MHTX Recruits Robert R. Proulx as New President and COO for Its Senior Scientific Subsidiary

Strengthening Management Team for Drive Toward Commercial Developments

January 14, 2015

Click here to view the printer friendly version of this press release

ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. has recruited Robert R. Proulx (pronounced “Pru”) to the position of President and Chief Operating Officer of its Senior Scientific LLC subsidiary, effective January 12. As previously announced, Gerald Grafe, former president of Senior Scientific, is remaining with Senior Scientific to focus on strategic relationships and intellectual property issues. Edward R. Flynn, PhD, founder of Senior Scientific, is remaining as Chief Scientist.

Mr. Proulx’s responsibilities will include building Senior Scientific’s core capabilities in nano-particle technology and expanding on the collaborations in place with the MD Anderson Cancer Center in Houston and The University of New Mexico Health Sciences Center, Albuquerque, to help further develop and strategically position Senior Scientific’s MRX diagnostic technology for the non-invasive early detection of cancer.

Mr. Proulx, age 57, is a veteran business executive with more than 25 years of leadership experience for both private and public companies in the life science and diagnostic device markets. Most recently, he served as Chief Commercial Officer and General Manager of U.S. Operations for Silicon Biosystems, Inc., whose image-based cell sorting technology is advancing personalized medicine initiatives in cancer through the molecular characterization of tumor heterogeneity. Earlier, he served as Vice President, Marketing & Sales at Nanogen, Inc., where he was responsible for worldwide corporate branding, product marketing and North American sales operations for the company’s in vitro diagnostic products. Prior to this, he held senior-level positions at Gene Logic Inc.; IGEN International, Inc.; Packard Instrument Company, Inc. and Bio-Tek Instruments, Inc. He has served on the board of directors of Semrock and PGXL Diagnostic Laboratories and has been a volunteer in the CONNECT Springboard Entrepreneurs in Residence program, helping nurture startups through early-stage business planning. His bachelor’s and master’s degrees are from The State University of New York at Albany and he is a graduate of the Executive Management Program at The Pennsylvania State University Smeal College of Business.

Mr. Proulx said, “With more than two and a half decades in the life science arena, I have helped bring to market a fair number of cutting-edge technologies. I am convinced that Senior Scientific’s MRX diagnostic technology represents a bold new step in cancer care, and I look forward to working with the rest of the management team as we continue to develop the technology and pursue the path to commercialization.”

Manny Tsoupanarias, CEO of Manhattan Scientifics, said, “Bob Proulx brings a tremendous amount of industry experience to Senior Scientific, and we are fortunate to have him serve as its new President and COO. We will undoubtedly benefit from his keen insights as we expand the development of our MRX diagnostic technology and enter the commercialization stage. At the same time, we are grateful for Gerald Grafe’s dedication as President and are gratified he will remain with Senior Scientific to guide our strategy and IP issues, while also ensuring a smooth transition in leadership.”

About Manhattan Scientifics

Manhattan Scientifics Inc. ( is focused on commercialization of disruptive technologies in the nano medicine space.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.